{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T06:39:22.091041+00:00","company":{"ticker":"CYRX","cik":1124524,"company_name":"Cryoport, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"151128f52958b9e91a1b709e479318f6f4f1b685","cik":1124524,"ticker":"CYRX","company_name":"Cryoport, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter (Q1) of 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$47.8 million"},"claim":"Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.","evidence_excerpt":"99.1) ---\n\nEX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport\nReports First Quarter 2026 Financial Results ● First\n quarter revenue grew 16% year-over-year to $47.8 million ● Commercial\n cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued\n expansion in approved CGT programs ● Life\n Sciences Services","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-26-054942","anchor_url":"https://secwatch.observer/filing/0001104659-26-054942#claim-151128f52958b9e91a1b709e479318f6f4f1b685","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm"},{"fact_type":"ma_transaction","fact_key":"3ed73c2503d6b4c18f01ee92b6a0a7d48a52f6bd","cik":1124524,"ticker":"CYRX","company_name":"Cryoport, Inc.","filed_at":"2025-06-13T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-06-11","consideration_text":"cash payments of approximately $200 million to Cryoport","counterparty":"designated affiliates of DHL Supply Chain International Holding B.V.","effective_date":"2025-06-11","item_codes_triggered":["2.01"]},"claim":"Cryoport, Inc. completed a disposition involving designated affiliates of DHL Supply Chain International Holding B.V. for cash payments of approximately $200 million to Cryoport (closed 2025-06-11).","evidence_excerpt":"specialty courier business, CRYOPDP, to DHL Group ( “ DHL ” ), one of the world ’ s leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. ​ Concurrently, Cryoport and DHL have established a strategic partnership aimed at enhancing their respective supply chain service offerings for the global life","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-25-008613","anchor_url":"https://secwatch.observer/filing/0001558370-25-008613#claim-3ed73c2503d6b4c18f01ee92b6a0a7d48a52f6bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124524/000155837025008613/0001558370-25-008613-index.htm"},{"fact_type":"earnings_release","fact_key":"47c7e152204722a1405d06837baf557e2302bfef","cik":1124524,"ticker":"CYRX","company_name":"Cryoport, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.43 per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$0.43 per share","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$54.6 million"},"claim":"Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.","evidence_excerpt":"filing. \n\n--- EX-99.1 (EXHIBIT 99.1) ---\n\nEX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024\nFinancial Results § Q1 2024 revenue of\n$54.6 million § 9% year-over-year\nincrease in Commercial Cell & Gene Therapy revenue § 9% year-over-year\nincrease in BioStorage/BioServices revenue § A total of 675 global\nclinical trials","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-24-058082","anchor_url":"https://secwatch.observer/filing/0001104659-24-058082#claim-47c7e152204722a1405d06837baf557e2302bfef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/0001104659-24-058082-index.htm"}]}